VEGFA and nonpapillary renal cell carcinoma: In the past decade, antiangiogenic drugs targeting vascular endothelial growth factor (VEGF), mechanistic target of rapamycin (mTOR) inhibitors, and immune checkpoint inhibitors (ICI) have rapidly expanded treatment options for metastatic ccRCC [3].